Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

77 posts / 0 new
Letzter Beitrag
b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

WARSICS wrote:

bought the "mini dip" bei .19

hehe.. gut gemacht.

hab gestern 185er nach gebaggert.. bin gespannt auf CC. werde für montag pulver bereit halten.

gn8

WARSICS
Bild des Benutzers WARSICS
Offline
Zuletzt online: 27.08.2013
Mitglied seit: 23.12.2010
Kommentare: 512
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

wie immer spannend und interessant. würde gerne wieder die 28 sehen im juni noch Lol

hast du gesehen, dass der run immer erst in den letzten 30 minuten geht?

Handelnder Holländer

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

ne is mir noch net spezifisch aufgefallen.

aber hier noch was, habs selber noch nicht angeschaut..

Kraig Biocraft Laboratories Announces Interview With CEO on Chartpoppers

Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced that the Company's CEO and founder, Kim Thompson, was recently featured in an interview with Mark Marek of Chartpoppers.com.

The archived audio interview is available at www.chartpoppers.com. The interview covers topics including Kraig's recent Sigma-Aldrich agreement and other corporate news events.

A copy of the transcript is posted in the news section of www.KraigLabs.com.

Additionally, the Company would like to remind everyone to submit questions for the Friday conference call to benh@ttfsco.com by tomorrow, Thursday, June 9. The teleconference will take place Friday, June 10, 2011, at 4:30 p.m. EDT, and call in details, including phone number and access codes, will be announced in a follow-up company release on the morning of the call.

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

Transcript of Chartpoppers Interview with Kraig Biocraft Laboratories CEO, Kim Thompson

In my opinion this interview was definitiely a set up piece to introduce new investors to Kraig Labs and direct them to the newly revised web site for pictoral and video DD. Red

http://www.kraiglabs.com/news.htm

June 2011

Mark Marek of Chartpoppers.com: Hello, welcome to Chartpoppers. Today we're joined by CEO Kim Thompson of Kraig Biocraft Laboratories. Kraig Biocraft Laboratories trades, and is quoted on the Over the Counter QB, under the symbol KBLB.

Kim, thanks for coming back to the show and updating us on the company.

Kim Thompson, CEO and founder, Kraig Biocraft Laboratories, Inc.: It's my pleasure Mark.

MM: Kim, we do appreciate you taking the time out. I know that you're a very busy man. You get a lot of calls since you cracked the code, but could you maybe spend a little time and tell us about how things have progressed since you made that announcement about six months ago and what developments have been in the Company?

KT: Absolutely, for your listeners who may not be familiar with the Company let me give a little bit of recap. In fact, when we last did an interview, Mark, it was shortly before we made that announcement with the University of Notre Dame and, essentially, what Kraig Biocraft Laboratories has been doing for the last several years, is working cooperatively with the University of Notre Dame to produce recombinant silk fibers.

Essentially, what we're doing is genetic engineering work, to try to create a platform for industrial scale production of recombinant silk fibers with similar mechanical characteristics to those found in nature, in spider silk. A material which is stronger, tougher than steel, highly flexible, which has physical and mechanical properties which are, in some ways, unmatched by materials which man can currently produce, and we really, I'm happy to say, back in September we were able to announce that we had largely achieved those goals.

In working cooperatively with the University, we were able to announce that we created approximately twenty different strains of transgenic silkworm, which we created using spider silk DNA sequences and that these silkworms were spinning recombinant silk, which was a fusion of spider silk and native silkworm silk and we announced, also at that joint press conference, that one of these silks, in particular, which we are tentatively calling “Monster Silk” was demonstrating physical properties of strength and elasticity, which significantly exceed that of natural silkworm silk. So, this was a major milestone for the Company, but a lot has happened since then.

What I can now reveal here in this interview, because we actually issued a press release about it, is that shortly after that announcement we entered into negotiations with one of the world's largest and most powerful biotechnology companies, Sigma-Aldrich, and we entered into negotiations with them in order to acquire licensing rights to use their very powerful Zinc Finger technology in our laboratories.

It's taken months to finalize that agreement, but we actually signed with them on April 8 and we are now introducing the Zinc Finger technology into our laboratory.

Sigma is currently designing and building customized Zinc Fingers for our use and this is and incredibly powerful technology, which will greatly accelerate our research and development efforts and also give us capabilities, which simply would have been impossible with any other technology.

It's also, from our perspective, something of a stamp of approval. Sigma came in and did due diligence on our Company, sent scientists into our lab to make sure our technology was solid before signing the deal with us and that was really the first time we let an outside company come in and actually put a scientist in our lab and review what we've done and what we've accomplished.

That was a very big deal for us. Sigma's now a minor shareholder of Kraig Biocraft Laboratories, as a result of this transaction, and we do anticipate that it will rapidly speed up our development of the next generation of products.

MM: Kim, could give us a little more understanding in what the technology that Life Science brings to the table enables you to do?

KT: To describe this technology that we've acquired through this licensing agreement with Sigma, it's going to be little difficult for those who aren't intimately familiar with the workings of biotechnology, but, in essence, and, this going to be a little more detailed than you want, but, in essence, this technology, this Zinc-Finger technology with Sigma, will allow us for the first time to make changes in the silkworm DNA that were completely impossible to make before. In the past, these genetic engineering technologies were almost like throwing darts at a gigantic dart board from a distance of, maybe, 200 yards and, in order the make the changes that you wanted, you would have to throw those darts really hard. You might have to throw 10,000 of them to get even close to your target and you probably would never get exactly get to your target, but you could get close. With 10,000 tries you might get lucky and get close.

With this Zinc-Finger technology, it's actually possible to walk right up to the dart board and push the dart in exactly where you want it the first try; the very first try.

To say that, and this is just my own thinking, but my own thinking here is that this will accelerate our product development by a factor of 50.

Instead of 10,000 tries to create a new recombinant silk fiber with extraordinary properties, we should be able to design the sequence, walk up to that dartboard and make that edit, make that change.

It's almost like editing a document in Microsoft Word. Go into the document, you see a word that's misspelled, you can change it. You want to change a period to a question mark, you can change it.

For the first time, this technology will give us the ability to do that with silkworm DNA. So, it's incredibly powerful. We're very excited. The deal's almost been six months in the works, but it's six months that I think are really going to pay off for Kraig Labs and its shareholders.

MM: Back in December 2010 you released a video, which deals with the basic technology of spider silk. I think it's important to mention that, because it could be a little hard to wrap your hands around the significance of these findings. Could you maybe give us a link or direction to that video?

KT: Probably the best, there have been several videos that we produced or that have been produced by, for example, the University of Notre Dame, on this technology. I would suggest going to the Company's website and going to our news page or our video page. There you can find links to several news stories and videos describing what we're doing. All of those videos predate the signing of Sigma deal, but you can certainly get an idea of the nature of the technology and what it is that we've accomplished, and what we're doing.

The website is www.KraigLabs.com . Those videos are available there and what you can see on those videos is actual silk fibers that we've produced, the recombinant silk fibers, using spider silk DNA.

You can see the genetic engineering technologies. You can see our genetically modified silkworms and, of course, you can see me and some of the scientists that have been working at Notre Dame on this project for the last several years.

I know, to many people who just learned Kraig Labs since September, it appears like we arrived on the scene overnight and we formed a company and created this transgenic silkworm, but it's actually been many, many years in the works.

There's been a lot of elbow work. A lot of hard work and effort by Kraig Labs and the University of Notre Dame to bring us to where we are now, which is a point where we actually have not just research and development, but actual product and are gearing up towards actual commercialization.

MM: Again, the Company is Kraig Biocraft Laboratories. The symbol can be found on the Over the Counter QB, under the symbol KBLB.

Kim, we're very excited to be following the Company during this crucial time. It's been a pleasure and thanks for speaking with us and we look forward to checking in a few months and just see where you are with the spider silk.

KT: Mark, it's been a pleasure, and we haven't forgotten that you came to interview us, even before we had the breakthrough announcement in September.

You know, since that time, we've obviously garnered a lot of interest and we received a lot of calls, but before that breakthrough announcement, we were relatively obscure and we haven't forgotten that you initiated some coverage of us before we were known and it's been a please to do another interview with you.

MM: Thank you very much, Kim. Have a good day.

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
amiforum (nach CC)

Reasons to expect very big news very soon:

We know that KBLB got the zinc fingers (a bit late) on June 10.

We know that it takes about a week (call it 5 to 10 days) to do the genetic modifications with the zinc fingers and test them to see if they were successful (a cell can be removed for testing after only 3 cell divisions (to the 8 cell stage)).

So as soon as 10 days from the CC, or around 20 June, if all goes well we may receive the news that the genetic modifications were successful.

That would be huge news. For reasons I discussed recently once the GMS have been made the odds for the worms producing pure spider silk are very high. (repeat from past post included below)

So within a few weeks after successful genetic modification with the zinc fingers KBLB is highly likely to have silkworms producing pure spider silk (the worms have to reach the cocoon stage to make silk to be tested). And that would be front page news and, IMHO, KBLB would be a penny stock no longer.

Some may try to sell now and hope to buy back in cheaper before the news has time to arrive. IMHO that is a very risky game. A lot of people will realize how close the news will be after the statement at the CC that the zinc fingers had been received and that it would take about a week to make the genetic modifications. The price may continue back up forcing sellers to pay a higher price if they want back in.

REPEATED MATERIAL: (full explanation of why the odds of success are so high)

Silkworms have been highly selected for silk production for thousands of years (tens of thousands of silkworm generations) The effect of such long term selection for commercial traits is to cause duplications of the genes for the traits selected for (in this case silk production genes) and to move the functions of the traits selected for away from other functions (i.e.: to different genes).

This happens because genes sometimes get duplicated. Such duplications tend to strengthen the traits the gene codes for (if for hair color, for example, more pigment gets produced so the hair is darker). If a duplicated gene is for one of the traits being selected for, the animal carrying it will be selected (if the trait is beneficial). Over extended time the result is that commercial animals that have been selectively bred for many generations will have duplicate copies of the genes for their most important traits.

Some genes have multiple functions. A mutation may remove one of the functions of a gene without affecting the other(s). When there are duplicate copies of a gene a mutation may cause one copy to lose one of its functions. Because there is another copy of the gene, the trait remains and it is not selected out. Then later another mutation causes a second copy to lose the function that remained in the first gene. The result is that where you started with one gene with two functions you now have two genes each with one of the functions of the original gene but not the other function. From two functions in one gene to two genes each with a different one of the original functions.

Over many generations of selection this process tends to cause the genes for important commercial traits (in silkworm the genes affecting silk production) to become separated from other functions (i.e.: on different genes instead of on the same gene) and often present in multiple copies.

Because of this isolation of function, the removal of the silkworm silk protein gene is unlikely to have any other function than the silk protein itself. That removes most of one of the few possible dangers of the removal of the silkworm silk protein gene.

The gene for spider silk was added to the worms before the removal of the silkworm silk gene is even being attempted. Because of their close similarities it is unlikely that the removal of the worm silk protein will leave a “gap” that the spider silk protein won't fill, but it is possible: for example, some enzyme important to proper folding of the silk protein might have its levels regulated by the presence of the worm silk protein and the molecule that recognizes the presence of the silkworm protein may not recognize the presence of the spider silk protein. That's very unlikely to occur given that the worms have already produced silk containing up to 80% spider silk protein (so if some regulation mechanism needed to recognize the silk protein but didn't recognize the spider version of the silk protein problems would almost certainly already occurred. But even if it did, it could readily be worked around: just take the equivalent silk recognition protein in the spider and take the sequence coding for the recognition region of that protein and replace the recognition region sequence of the worm protein with it. There are tools to do all that, and thanks to the zinc fingers doing that genetic modification will also be easy. And since KBLB has 200 spider genes, all related to silk production it's highly likely that it will already have any such genes needed.

There are a few other potential problems, all very unlikely for similar reasons given that the worms have already produced silk with up to 80% spider protein successfully and shown no problems. And there are workarounds available for them as well should they occur.

Bottom line: the removal of the silkworm silk protein genes from the worms is almost certain to be successful the first time given the excellent track record of SGMO and SIAL's zinc fingers. (as noted previously some other researchers have had more difficulty with zinc fingers but, as I described in great detail in a recent post, SGMO/SIAL's zinc fingers have a vastly superior technology and an excellent track record. I also posted a scientific study in a peer reviewed journal of an experiment that showed that zinc fingers work in silkworms (I'll repost all of that late tonight or early tomorrow).

And the successful removal of the silkworm silk protein gene is dead certain to prevent any worm protein from being in any silk produced. It would be physiologically impossible for the worms to produce silkworm silk protein without a copy of the gene for it.

And the removal of the silk worm silk protein is very unlikely (as per the above discussion) to cause any problems with silk production and, even if it does, there is likely to be a workaround available.

So IMHO the odds of success look very high. If the genetic modifications work on the first try we should know by about 17 to 20 June (give or take a bit). If so, in just a few weeks we will also know whether or not the worms produce pure spider silk. (A bit longer if Kim sends the silk out for independent tests before releasing results.)

If the ZF modifications don't work on the first try that would NOT be a show-stopper. Zinc fingers work the first time most of the time but not 100% of the time. A simple repetition with a possible tweaking of the zinc fingers would likely be successful.

Nothing, of course, is guaranteed. But in this case the odds are very high for success.

WARSICS
Bild des Benutzers WARSICS
Offline
Zuletzt online: 27.08.2013
Mitglied seit: 23.12.2010
Kommentare: 512
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

Quote:

We know that it takes about a week (call it 5 to 10 days) to do the genetic modifications

präzise zeitangabe. daytrade das jetzt mal und schaue wie es läuft heute

edit 16:44: genial! du kannst hier seit 20 minuten zu ,149 kaufen und gleich wieder zu ,159 verkaufen. hammer!

Handelnder Holländer

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

joa, ohne rumor und g news seh ich da noch etwas platz nach unten

close ü 162 wär nett

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

grad auf der 0.105er linie...mal sehn vlt. hält die wieder!?

WARSICS
Bild des Benutzers WARSICS
Offline
Zuletzt online: 27.08.2013
Mitglied seit: 23.12.2010
Kommentare: 512
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

bienvenue a la resistance... errrr support in dem fall.

0.104 -0.023 (-18.03%)

ich kaufe ein. hier hat sich historisch unterstützung gebildet. bei 0.089 setze ich den stop loss. just to make sure.

Handelnder Holländer

WARSICS
Bild des Benutzers WARSICS
Offline
Zuletzt online: 27.08.2013
Mitglied seit: 23.12.2010
Kommentare: 512
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

edit: ist schon jetzt schwierig was für 104 zu bekommen. hoffe ich kriege das noch unter 11 hin... :?

edit: so langsam wirds programm... biete seit .104 mit... bekomme nichts... lasse .109 jetzt einfach drin und gehe kaffee trinken. schade! die 10% hätte ich mir gerne eingesteckt! :evil:

Handelnder Holländer

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

Kraig Biocraft Laboratories Announces $1.5 Million Agreement With Calm Seas Capital

Kraig Biocraft Labs (QB) (USOTC:KBLB)

12:23PM

Intraday Stock Chart

Today : Thursday 30 June 2011

Click Here for more Kraig Biocraft Labs (QB) Charts.

Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced that the Company has entered into a new financing agreement with Calm Seas Capital.

The new credit facility supplements the existing agreement with Calm Seas Capital and provides for up to $1.5 million over a 24 month period.

"Calm Seas has been a solid funding source and their new expanded capital commitment strengthens Kraig's position, as we move forward," stated Kim Thompson, the Company's CEO and founder. "The new credit facility signifies an important step in executing our commercialization plan and the proceeds will enhance our capacity to pursue the ramp-up phase of our recombinant product."

The financing agreement with Calm Seas Capital was recently disclosed in an 8k filing and that filing, including details of the agreement, are available on the EDGAR system.

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

Biggrin

WARSICS
Bild des Benutzers WARSICS
Offline
Zuletzt online: 27.08.2013
Mitglied seit: 23.12.2010
Kommentare: 512
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

tja mein freund. geduld und weise investition zahlt sich heute wieder mal aus. congrats. das sieht gut aus. ich lasse laufen!

0.124

+0.018 (16.98%)

Handelnder Holländer

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

wir werden sehn Wink

0.105 hat heut wieder gehalten

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

WARSICS
Bild des Benutzers WARSICS
Offline
Zuletzt online: 27.08.2013
Mitglied seit: 23.12.2010
Kommentare: 512
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

die 10.04/05 bleibt magisch!

heute kommen die news:

corrupt link

wird den titel nicht explodieren lassen, aber ganz galante weg von der support marke ziehen und glatt durch den 1. widerstand. sieht so aus, als haben wir wieder ein gutes timing erwischt b00n! :twisted:

Handelnder Holländer

WARSICS
Bild des Benutzers WARSICS
Offline
Zuletzt online: 27.08.2013
Mitglied seit: 23.12.2010
Kommentare: 512
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

link erst ma nich anklicken, glaube ich habe mir da einen virus gezogen... gopf

Handelnder Holländer

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
erste früchtchen mit Sigma s ZF technologie

jup wunderbar..scheint gut zu kommen.

Kraig Biocraft Laboratories Announces the Completion of Its First Zinc Finger Micro-Insertions

Kraig Biocraft Labs (QB) (USOTC:KBLB)

Intraday Stock Chart

Today : Tuesday 5 July 2011

Click Here for more Kraig Biocraft Labs (QB) Charts.

Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced the completion of its first round of zinc finger micro-insertions.

"We are very excited to be performing these genetic engineering feats so soon after signing the agreement for their use with Sigma-Aldrich," said CEO and company founder, Kim K. Thompson. "The immediate results from this first round of generic insertion are truly encouraging, as we observed a high hatch rate within a few days of employing the new technology."

In April, Kraig entered into an agreement with Sigma-Aldrich to use Sigma's powerful zinc finger technology to accelerate Kraig's scientific research and product development. The zinc fingers are an effective genetic engineering technology that the Company is using to create the next generation of biomaterials, including recombinant spider silks, for the textile and technical textile markets.

"The company has very high expectations for these newly hatched silkworms and we are watching their development closely," Thompson continued. "As of yet, the caterpillars are far too small for us to determine whether we hit our genetic target. So far, the technology is performing as anticipated and, even as we monitor the development of these silkworms, we are preparing for the next round of micro-insertions."

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

mal andere Töne von hotstocked...

nich das übliche one man company gepimpe..

http://www.hotstocked.com/article/14461/.html

WARSICS
Bild des Benutzers WARSICS
Offline
Zuletzt online: 27.08.2013
Mitglied seit: 23.12.2010
Kommentare: 512
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

nice one. einzig dieser titel rettet ein tief rotes portfolio heute.

habe mir übrigens noch threshold pharma gezogen. sauberer pick.

Handelnder Holländer

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Re: erste früchtchen mit Sigma s ZF technologie

b00n wrote:

jup wunderbar..scheint gut zu kommen.

Kraig Biocraft Laboratories Announces the Completion of Its First Zinc Finger Micro-Insertions

Kraig Biocraft Labs (QB) (USOTC:KBLB)

Intraday Stock Chart

Today : Tuesday 5 July 2011

Click Here for more Kraig Biocraft Labs (QB) Charts.

Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced the completion of its first round of zinc finger micro-insertions.

"We are very excited to be performing these genetic engineering feats so soon after signing the agreement for their use with Sigma-Aldrich," said CEO and company founder, Kim K. Thompson. "The immediate results from this first round of generic insertion are truly encouraging, as we observed a high hatch rate within a few days of employing the new technology."

In April, Kraig entered into an agreement with Sigma-Aldrich to use Sigma's powerful zinc finger technology to accelerate Kraig's scientific research and product development. The zinc fingers are an effective genetic engineering technology that the Company is using to create the next generation of biomaterials, including recombinant spider silks, for the textile and technical textile markets.

"The company has very high expectations for these newly hatched silkworms and we are watching their development closely," Thompson continued. "As of yet, the caterpillars are far too small for us to determine whether we hit our genetic target. So far, the technology is performing as anticipated and, even as we monitor the development of these silkworms, we are preparing for the next round of micro-insertions."

ja eben, diese ZF technologie...

hier kam grad was von sigma zu dem thema..

Sigma® Life Science Reaches Milestone in Gene Editing with Increased Affordability for CompoZr® ZFNs and the Expansion of Knockout ZFNs to Include Every Gene in Mice and Rats

Advances in technology platform and new production center result in more content and less expensive CompoZr ZFNs

ST. LOUIS, Aug. 3, 2011 /PRNewswire/ -- Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq:SIAL), today announced a major breakthrough in the development of its proprietary CompoZr zinc finger nuclease (ZFN) technology with the release of more Knockout ZFNs covering the entire genomes of both mice and rats, while the pricing of products within the CompoZr ZFN portfolio by half. A new dedicated high-throughput manufacturing center, together with advances in ZFN design algorithms and production processes, has led to cost reductions in the development and production for both CompoZr Custom and Knockout ZFNs. This has allowed Sigma Life Science to extend the range of its Knockout ZFNs and to make ZFN technology more affordable to the scientific community. For more information visit www.sigma.com/zfn.

The increased capacity of the new manufacturing facility allows Sigma Life Science to rapidly develop its CompoZr Knockout ZFN portfolio, bringing the advantages of this technology to many previously underserved research fields. The expansion of the Knockout ZFNs for every mouse and rat gene is in its initial phase, which complements the existing range of Knockout ZFNs for the entire human genome. This exciting milestone in genome editing can enable the scientific community to pursue previously unachievable research quickly and easily with validated tools, avoiding the cost, time and uncertainty associated with other techniques.

ZFN technology has been widely recognized as the most efficient and versatile method of genetic engineering for cell lines and whole organisms, offering precisely targeted, permanent and heritable modifications in a fraction of the time required using more traditional technologies. ZFNs have been broadly adopted within the biotechnology and pharmaceutical sectors, but the high cost of designing and manufacturing CompoZr ZFNs has at times limited the research community's access to this technology. To address this issue, Sigma Life Science invested heavily in advancing both its design and production processes to drive down costs and in an effort to help researchers accelerate scientific discovery. The new development and manufacturing facility is expected to ensure affordable pricing for Sigma's complete range of CompoZr ZFN offerings and further extend the scope of this powerful genome editing technology.

David Smoller, Chief Scientific Officer at Sigma Life Science, commented, "Sigma Life Science has reached another milestone in our quest to provide the research community with greater access to ZFN technology. CompoZr ZFNs are now available in multiple formats, multiple species and at more accessible pricing. It is now our objective to continue to drive the development of new applications for CompoZr ZFNs, while maintaining this vital affordability."

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "can enable," "expected," "our objective," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that CompoZr ZFN Technology will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with that CompoZr ZFN Technology could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

WARSICS
Bild des Benutzers WARSICS
Offline
Zuletzt online: 27.08.2013
Mitglied seit: 23.12.2010
Kommentare: 512
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

noch keine ergebnisse von der 1st round aber schon 2nd round am durchjagen. wird den kurs in dem heutigen umfeld nicht so sehr beflügeln wie gewünscht aber zumindest im akzeptablem bereich halten während der rest den bach runter geht

http://www.marketwatch.com/story/kraig-biocraft-laboratories-completes-scheduled-second-round-of-micro-insertions-using-zinc-finger-technology-2011-08-08?reflink=MW_news_stmp

Handelnder Holländer

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

zurück auf ma 200 hoffe auf knacken ma20.. dann dürften hurti einige prozente drin liegen.

WARSICS
Bild des Benutzers WARSICS
Offline
Zuletzt online: 27.08.2013
Mitglied seit: 23.12.2010
Kommentare: 512
KBLB

hier sieht es wieder passabel und freundlich aus nach den neulichen tauchern. bin treu geblieben und halte wieder kurs gen gewinnzone.

watch it!

Handelnder Holländer

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

hier was von nem SIGMA Aldrich typen....

read it

http://www.labnews.co.uk/features/silk-spinning-the-genetically-modified...

die sache scheint auf gutem weg zu sein

-----

News von KB erwartet, gem. letzter PRS, im Herbst.

gestern ansehlicher kaufdruck.

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
news

Kraig Biocraft Laboratories, Inc. Signs Spider Silk Commercial License Agreement With the University of Notre Dame

Kraig Biocraft Labs (QB) (USOTC:KBLB)

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (PINKSHEETS: KBLB) (the "Company" or "Kraig") announced that it signed a commercial license agreement with the University of Notre Dame regarding spider silk technologies.

The agreement awards Kraig the exclusive worldwide commercial rights to certain spider silk technologies which the Company jointly developed with the University of Notre Dame. Pursuant to the agreement, the University of Notre Dame will become a shareholder of the Company. The University will also receive a 2% royalty of the Company's net sales of products which incorporate the technology.

The subject of the agreement is the definitive spelling out of rights for the commercialization of what the Company refers to as "generation one" spider silk technology. The agreement confirms the Company's exclusive right to the commercial development of spider silk textiles derived from the subject technology.

"Due to the significance of this technology it was important that we craft an agreement that benefits Kraig, our shareholders and the University," stated Kim Thompson, Company CEO and founder. "We are very happy to welcome the University of Notre Dame as our newest shareholder. We are also very happy to formally consummate this commercial license agreement covering the commercial rights to this exciting technology which we have been developing with the University."

"Our collaboration with university laboratories has been fundamental to the rapid progress we have made in the development of spider silk," Thompson continued. "The commercial license agreement reflects that sentiment and lays the groundwork for the Company's commercialization of spider silk technologies."

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
newsalert

Date : 11/14/2011 @ 4:05PM

Kraig Biocraft Laboratories Announces Creation of Seven New Strains of Transgenic Silkworms Using Zinc Finger Nuclease Techno...

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (PINKSHEETS: KBLB) (the "Company" or "Kraig") announced that researchers at the University of Notre Dame, utilizing customized zinc finger configurations licensed to Kraig from Sigma-Aldrich, succeeded in creating seven or more strains of transgenically modified silkworms.

The Company believes that this breakthrough removes the largest barrier to pure spider silk technology.

The zinc finger nuclease were designed to cleave the silkworm's native heavy chain gene. The resulting silkworms were inter-mated to produce 50 mating pairs, which each produced clutches of approximately 100 eggs. Genetic testing designed to detect mutations at the site of zinc finger cleavage were preformed and the testing recovered positive results for zinc finger disruption, therefore knockout of the native heavy chain gene in embryos, from 7 of the first 13 mating pairs, analyzed.

"This success rate is much higher than we ever expected," said Company CEO and founder Kim Thompson. "The laboratory reports that seven new strains of transgenics have been confirmed so far."

"The bottom line is that zinc finger nuclease works exceedingly well for our particular targets. Our adopting this technology was a bit of a gamble at the time, but it turns out to have been one of the smartest moves we could have made. We view this genetic knockout as the achievement of our greatest scientific goal for 2011," continued Thompson.

Dr. Malcolm Fraser reported, "We anticipate that we will be able to recover homozygous knockout silkworms from these pools of embryos with little difficulty. These homozygous commercial strain heavy chain knockouts will serve as a more effective platform technology for rapid development and commercialization of future spider silk transgenics, allowing us to readily recover commercially ready spider silk transgenics by simply screening for the production of cocoons."

Dr. Fraser concluded, "This Zinc Finger approach exceeded our best expectations in terms of its capabilities for introducing mutations in silkworms. The frequency of mutation events and the capability of working directly with the commercial strains give a much more rapid route to new, commercially relevant transgenics."

The Company believes that the next generation of its technology, which utilizes zinc fingers, will significantly expand its product capabilities and target markets.

Thompson further stated, "Dr. Fraser and his team have once again verified our scientific models. The results also serve as proof of efficacy for the creation of targeted transgenics, and confirm our confidence in the power of zinc finger technologies. We now believe that we have both the platform and targeted transgenic capabilities which we need to create Generation II and Generation III technical textiles."

The Company is already ramping up production of Monster Silk, its previously disclosed product which is the subject of the Company's recent licensing agreement with the University of Notre Dame. While Monster Silk is targeted for conventional applications, the Company believes that the technology described in today's announcement will ultimately unlock applications for technical textiles and broader markets. :!:

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
News around the world...

News around the world...

 

http://uk.onlinenigeria.com/news/breaking-news/5533-scientists-genetically-engineer-spider-silk-using-silkworms.html 

http://www.telegraph.co.uk/science/science-news/8988901/Scientists-make-silkworms-spin-spider-webs.html 

http://www.independent.co.uk/news/science/well-it-worked-for-peter-parker-genetic-scientists-unleash-power-of-the-spider-web-6284220.html 

http://www.newsbullet.in/world/52-more/23877-spider-twist-leads-to-hybrid-silk-yarn 

http://manchesteronlinenews.co.uk/2012/scientists-genetically-engineer-spider-silk-using-silkworms/ 

http://www.anhourago.eu/show.aspx?l=49222303&d=504 

http://in.news.yahoo.com/spider-twist-leads-hybrid-silk-yarn-231415513.html 

 

oben ist da jeweils von der UNI wyoming die rede nachfolgend der zusammenhang;

 

"The commercial license agreement which the Company signed last month with the University covers these technologies and gives Kraig Biocraft Laboratories the exclusive global right to market the products and technologies described in the patent application," continued Thompson. "We see this filing in Geneva, coupled with our license agreements with the University of Wyoming, the University of Notre Dame and our license agreement with Sigma-Aldrich, as the corner stones of our expanding intellectual property portfolio. We feel well armed as we move forward to bring recombinant spider-silk to market." 


http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-filing-international-patent-application-spider-pinksheets-kblb-1596145.htm 

apropos, aktuell günstig bewertet aus meiner sicht

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
 

 

Kraig Biocraft Laboratories Announces Peer Reviewed Publication of Spider Silk and Transgenic Silkworm Breakthroughs

 

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (PINKSHEETS: KBLB) is very happy to start the New Year by announcing that the Journal Proceedings of the National Academy of Sciences published a peer-reviewed scientific article describing the breakthrough creation of a spider silk fusion fiber, which was achieved by university scientists within the University of Wyoming and the University of Notre Dame, who are working cooperatively with Kraig Biocraft Laboratories.

......

"The fact that a publication as prestigious as Proceedings of the National Academy of Sciences has chosen to publish these results speaks for itself as to the significance of the scientific breakthrough," said Company founder and CEO, Kim K Thompson. "When I founded Kraig many people in both the business and scientific community said that what we were setting out to do was impossible. By maintaining a focused vision and by recruiting the very best minds in molecular biology, we have made the impossible a tangible reality."

......

 

 

"Congratulations to the scientific team as well as to the University of Notre Dame and the University of Wyoming. They deserve the accolades they are receiving with this publication," continued Thompson. "Our next steps are to commercialize these developments while accelerating our development of even more advanced products. The commercial license agreement we signed in the fourth quarter of 2011 was an essential element of the former. As we move toward commercialization of these fibers, we are simultaneously moving into an advanced stage in the development of new, second generation spider silk polymers."

......

http://ih.advfn.com/p.php?pid=nmona&article=50627101

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
FOX NEWS

FOX NEWS

 

Genetically Modified Silkworm Brings Spider-Man Web Closer to Reality

Read more: http://www.foxnews.com/scitech/2012/01/05/genetically-modified-silkworm-brings-spider-man-web-closer-to-reality/#ixzz1ibQB1zKE

 

 

Seiten